Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
PR Newswire•01/10/2026•07:00 ET
1
Key Highlights
- ➤Foundayo 17.2 mg associated with 57% lower predicted type 2 diabetes risk versus placebo
- ➤Foundayo 17.2 mg associated with 18% lower predicted cardiovascular disease risk versus placebo
- ➤Foundayo 5.5 mg associated with 45% lower predicted type 2 diabetes risk versus placebo
- ➤Foundayo 9 mg associated with 50% lower predicted type 2 diabetes risk versus placebo
Expert Statements
Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health
“For many people living with obesity or overweight, the concern isn't just what the scale says today, it's whether their future could include type 2 diabetes or heart disease.”
Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health
“These additional analyses of ATTAIN-1 show that Foundayo was associated with a lower predicted long-term risk of both conditions, in addition to meaningful weight loss.”
Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health
“We've also seen evidence that treating obesity and reducing the risk of its downstream consequences, like cardiovascular disease and type 2 diabetes, can meaningfully lower healthcare costs.”
Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health
“That gives us real optimism about what long-term Foundayo use could mean, both for patients and for the broader healthcare system.”
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease PR Newswire
In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo
Get started
Create a free account to read the full story.